RT Journal Article
SR Electronic
T1 Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2493
OP 2501
VO 35
IS 5
A1 CARL BLOMBERG
A1 JONAS NILSSON
A1 GEORG HOLGERSSON
A1 PER EDLUND
A1 MICHAEL BERGQVIST
A1 LINDA ADWALL
A1 SIMON EKMAN
A1 DANIEL BRATTSTRÖM
A1 STEFAN BERGSTRÖM
YR 2015
UL http://ar.iiarjournals.org/content/35/5/2493.abstract
AB Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy mainly localized to the pleura. Malignant mesothelioma grows highly invasive into surrounding tissue and has a low tendency to metastasize. The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. The present review aims at describing available data from randomized trials considering systemic medical treatment for this patient category.